• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Stat, Applied XL: COVID-19 Trials Too Small to Give Clear Answers

Article

Almost 40% of trials are designed to have fewer than 100 patients.

An analysis of COVID-19 treatment and prevention trials found that many of the 1,200 studies underway won't produce clear results because they are too small or flawed in other ways.

"It's a huge amount of wasted effort and wasted energy when actually a bit of coordination and collaboration could go a long way and answer a few questions," Martin Landray, a professor of medicine at Oxford University was quoted as saying in a Stat story posted today.

Stat, the Boston-based biotech news website, and Applied XL, a computational journalism start-up, joined forces to conduct the analysis, which sifted through data extracted from clinicaltrials.gov, the federal government's comprehensive database of clinical trials.

The Stat-Applied XL project found that 39% of the studies are designed to enroll fewer than 100 patients. Statistically siginficant results in studies that size can be difficult to achieve. The analysis also found that a sixth of the trials are of the malaria drugs, hydroxychloroquine and chloroquine. So far, neither have been shown to be effective as COVID-19 treatments. The Stat story notes that 237,000 of the 685,000 of the patient volunteers were to be enrolled in trials of hydroxychloroquine and chloroquine.

"Since patients willing to enter studies are one of the scarcest resources in medicine, this means that other potential treatments, such as ivermectin and favipavir, were not studied," says Stat.

The story points out, though, that researchers have had some success in sorting out which COVID-19 interventions work and which do not. The prime example is the RECOVERY trial, of which Landray is one of the chief investigators. Results from RECOVERY identified dexamethasone, an inexpensive corticosteroid, as effective in reducing mortality among COVID-19 patients put on ventilators.

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Related Content
© 2024 MJH Life Sciences

All rights reserved.